Study wrapper · #1276
Oral Colon- and Mitochondria-Targeted Nanoparticles Alleviate Ulcerative Colitis by Reeducating Macrophage Polarization via SIRT3/FOXO3a-Mediated Mitochondrial Restoration.
Editor's note
SS-31 here is the targeting element in a nanoparticle rather than the agent under test, so the results speak to the delivery system as a whole and cannot be read as evidence for SS-31 on its own. The mechanistic chain is well documented — mitochondrial membrane potential, ATP, ROS, mitophagy and macrophage phenotype all measured — but the model is DSS-induced colitis in mice, a short-course chemical injury that responds to many things that fail in human inflammatory bowel disease. No human data and no oral pharmacokinetics in people. Relevant to readers tracking SS-31 and elamipretide as mitochondrial-targeting tools.
Plain-language abstract
Researchers built a coated oral nanoparticle that survives the stomach, releases in the colon, and uses the mitochondria-targeting peptide SS-31 to steer its cargo into the mitochondria of immune cells. In cell tests the particles restored mitochondrial function and pushed macrophages from an inflammatory to a repair-oriented state via SIRT3/FOXO3a signalling. In mice with chemically induced colitis, oral dosing reduced disease severity, lowered inflammatory cytokines, raised IL-10 and restored gut-barrier proteins.